ArticleJournal of acquired immune deficiency syndromes (1999)2018
Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV.
Article in Journal of acquired immune deficiency syndromes (1999), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.International journal of antimicrobial agents · 2018Pooled it
- Guideline
- Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021 · on this mapTrial
- Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Trial
- Development of a heart failure with preserved ejection fraction risk prediction score in primary care settings with a high HIV prevalence.Open heart · 2026Observational
- Long-Acting Cabotegravir and Rilpivirine Treatment for HIV in Patients With Kidney Failure: Two Cases of Successful Transition to Long-Acting Injectable HIV Therapy.Kidney medicine · 2025Article
- Antiretroviral Therapy and Cardiovascular Risk in People With HIV in the United States-An Updated Analysis.Open forum infectious diseases · 2024Article
- Cardiovascular Risk Estimation Is Suboptimal in People With HIV.Journal of the American Heart Association · 2024Article
- Association of Coronary Wall Thickening and Diminished Diastolic Function in Asymptomatic, Low Cardiovascular Disease-Risk Persons Living with HIV.Radiology. Cardiothoracic imaging · 2024Observational
- Evolving mechanisms and presentations of cardiovascular disease in people with HIV: implications for management.Clinical microbiology reviews · 2024Review
- Prevention and treatment of cardiovascular disease in HIV: practical insights in an evolving field.Topics in antiviral medicine · 2023Article
- HIV infection.Nature reviews. Disease primers · 2023Review
- Association of Antiretroviral Therapy with Platelet Function and Systemic Inflammatory Response in People Living with HIV: A Cross-Sectional Study.Microorganisms · 2023Article
- Longitudinal Changes in Subclinical Vascular Disease in Ugandan Youth With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Observational
- Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy.Journal of clinical medicine · 2022Article
- Association of the VACS Index With Hospitalization Among People With HIV in the NA-ACCORD.Journal of acquired immune deficiency syndromes (1999) · 2022Article
- Sex Differences in Non-AIDS Comorbidities Among People With Human Immunodeficiency Virus.Open forum infectious diseases · 2021Review
- Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States.AIDS research and therapy · 2021Article
- Cardiovascular disease and prevention among people living with HIV in South Florida.Medicine · 2021 · on this mapObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 16 institutions in 3 countries.
Funding
Abstract
backgroundThere is persistent confusion as to whether abacavir (ABC) increases the risk of myocardial infarction (MI), and whether such risk differs by type 1 (T1MI) or 2 (T2MI) MI in adults with HIV.
methodsIncident MIs in North American Cohort Collaboration on Research and Design participants were identified from 2001 to 2013. Discrete time marginal structural models addressed channeling biases and time-dependent confounding to estimate crude hazard ratio (HR) and adjusted hazard ratio (aHR) and 95% confidence intervals; analyses were performed for T1MI and T2MI separately. A sensitivity analysis evaluated whether Framingham risk score (FRS) modified the effect of ABC on MI occurrence.
resultsEight thousand two hundred sixty-five adults who initiated antiretroviral therapy contributed 29,077 person-years and 123 MI events (65 T1MI and 58 T2MI). Median follow-up time was 2.9 (interquartile range 1.4-5.1) years. ABC initiators were more likely to have a history of injection drug use, hepatitis C virus infection, hypertension, diabetes, impaired kidney function, hyperlipidemia, low (<200 cells/mm) CD4 counts, and a history of AIDS. The risk of the combined MI outcome was greater for persons who used ABC in the previous 6 months [aHR = 1.84 (1.17-2.91)]; and persisted for T1MI (aHR = 1.62 [1.01]) and T2MI [aHR = 2.11 (1.08-4.29)]. FRS did not modify the effect of ABC on MI (P = 0.14) and inclusion of FRS in the MSM did not diminish the effect of recent ABC use on the combined outcome.
conclusionsRecent ABC use was associated with MI after adjustment for known risk factors and for FRS. However, screening for T1MI risks may not identify all or even most persons at risk of ABC use-associated MIs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.